A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously. Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies

Trial Profile

A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously. Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs RG 6146 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 03 Apr 2017 Planned End Date changed from 1 Aug 2017 to 31 Dec 2017.
    • 03 Apr 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top